The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefit was demonstrated for invasive bacterial infections (Casadevall & Scharff, 1994), for various viral diseases (Janeway, 1945; Hammon et al, 1953), as well as for anti‐fungal therapy (Bugli et al, 2013)”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Casadevall & Scharff, 1994
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
The principles and practice of medicine
(1938) · The American Journal of Surgery · doi:10.1016/s0002-9610(38)91188-2 · Cited by 1,657
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J. M., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS
Flexner, S. (1913) · The Journal of Experimental Medicine · doi:10.1084/jem.17.5.553 · Cited by 175
Cooper, G. M., Rosenstein, C., Walter, A. W., & Peizer, L. R. (1932) · The Journal of Experimental Medicine · doi:10.1084/jem.55.4.531 · Cited by 96
SEROLOGICAL RELATIONSHIPS AMONG MENINGOCOCCI
Branham, S. E. (1953) · Bacteriological Reviews · doi:10.1128/br.17.3.175-188.1953 · Cited by 84
In Vitro Antibodies: Strategies for Production and Application
Morrison, S. L. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001323 · Cited by 83
Experimental Meningococcal Infection in Mice
Miller, C. P. (1933) · Science · doi:10.1126/science.78.2024.340 · Cited by 77
A BIOLOGIC CLASSIFICATION OF PNEUMOCOCCI BY MEANS OF IMMUNITY REACTIONS
Dochez, A. R. (1913) · JAMA · doi:10.1001/jama.1913.04350100005003 · Cited by 74
Cited by
Sorted by citations
Vaccines for preventing pneumococcal infection in adults
Moberley, S. A., Holden, J., Tatham, D. P., & Andrews, R. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000422.pub3 · Cited by 970
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 904
Self-citationDeployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B. H., Winters, J. L., van Buskirk, C. M., Grossman, B. J., Joyner, M. J., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 805
Self-citationAn Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H. D., Shannar, A., Peter, R. M., Chou, P. J., Li, S. N., Hudlikar, R. R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 600
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 542
Self-citationConvalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031893 · Cited by 509
Self-citationVaccines for preventing pneumococcal infection in adults
Moberley, S. A., Holden, J., Tatham, D. P., & Andrews, R. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000422.pub2 · Cited by 387
Joyner, M. J., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., et al. (2020) · medRxiv · doi:10.1101/2020.08.12.20169359 · Cited by 337
Self-citationEmerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I., Ψαλτοπούλου, Θ., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 335
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Self-citationIntegrative Physiology of Pneumonia
Quinton, L. J., Walkey, A. J., & Mizgerd, J. P. (2018) · Physiological Reviews · doi:10.1152/physrev.00032.2017 · Cited by 330
Antibody immunity and invasive fungal infections
Casadevall, A. (1995) · Infection and Immunity · doi:10.1128/iai.63.11.4211-4218.1995 · Cited by 282
Self-citationA multifunctional bispecific antibody protects against Pseudomonas aeruginosa
DiGiandomenico, A., Keller, A. E., Gao, C., Rainey, G. J., Warrener, P., Camara, M. M., Bonnell, J. C., Fleming, R. L., Bezabeh, B. Z., Dimasi, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009655 · Cited by 279
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Forthal, D. N. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0019-2014 · Cited by 266
Natural history of COVID-19 and current knowledge on treatment therapeutic options
dos Santos, W. G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110493 · Cited by 235
Ben‐Nathan, D., Lustig, S., Tam, G., Robinzon, S., Segal, S., & Rager‐Zisman, B. (2003) · The Journal of Infectious Diseases · doi:10.1086/376870 · Cited by 219
Glatman‐Freedman, A., & Casadevall, A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.3.514 · Cited by 214
Self-citationDiGiandomenico, A., Warrener, P., Hamilton, M. M., Guillard, S., Ravn, P., Minter, R., Cámara, M. M., Venkatraman, V., MacGill, R. S., Lin, J., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120033 · Cited by 177
Monoclonal antibody-based therapies for microbial diseases
Saylor, C., Dadachova, E., & Casadevall, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.105 · Cited by 172
Self-citationGeneration and Characterization of a Protective Monoclonal Antibody to Pseudomonas aeruginosa PcrV
Frank, D. W., Vallis, A. J., Wiener‐Kronish, J. P., Roy‐Burman, A., Spack, E. G., Mullaney, B. P., Megdoud, M., Marks, J. D., Fritz, R. B., & Sawa, T. (2002) · The Journal of Infectious Diseases · doi:10.1086/341069 · Cited by 171
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166
“Clinical benefit was demonstrated for invasive bacterial infections (Casadevall & Scharff, 1994), for various viral diseases (Janeway, 1945; Hammon et al, 1953), as well as for anti-fungal therapy (Bugli et al, 2013), and polyclonal antibody products were licensed for several viruses.”
BackgroundXu, Y., Li, X., Jin, L., Zhen, Y., Lu, Y., Li, S., You, J., & Wang, L. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.07.003 · Cited by 166
More Is Not Necessarily Better: Prozone-Like Effects in Passive Immunization with IgG
Taborda, C. P., Rivera, J., Zaragoza, Ó., & Casadevall, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3621 · Cited by 166
Self-citationCasadevall, A. (2002) · Emerging infectious diseases · doi:10.3201/eid0808.010516 · Cited by 164
Self-citationPoelstra, K. A., Barekzi, N. A., Rediske, A. M., Felts, A. G., Slunt, J. B., & Grainger, D. W. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.10069 · Cited by 158
Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
Zurawski, D. V., & McLendon, M. K. (2020) · Antibiotics · doi:10.3390/antibiotics9040155 · Cited by 154
Unveiling the Impact of Antibiotics and Alternative Methods for Animal Husbandry: A Review
Low, C. X., Tan, L. T., Mutalib, N. A., Pusparajah, P., Goh, B. H., Chan, K., Letchumanan, V., & Lee, L. (2021) · Antibiotics · doi:10.3390/antibiotics10050578 · Cited by 163
History of passive antibody administration for prevention and treatment of infectious diseases
Graham, B. S., & Ambrosino, D. M. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000154 · Cited by 153
Mukherjee, S., Lee, S. C., & Casadevall, A. (1995) · Infection and Immunity · doi:10.1128/iai.63.2.573-579.1995 · Cited by 153
Self-citationHark back: Passive immunotherapy for influenza and other serious infections
Luke, T. C., Casadevall, A., Watowich, S. J., Hoffman, S. L., Beigel, J. H., & Burgess, T. H. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d44c1e · Cited by 150
Self-citationDevelopments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host
Pirofski, L., & Casadevall, A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.1 · Cited by 138
Self-citationValadon, P., Nussbaum, G., Boyd, L. F., Margulies, D. H., & Scharff, M. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0438 · Cited by 135
Self-citationTherapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?
Dimitrov, D. S., & Marks, J. D. (2009) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-554-1_1 · Cited by 132
mRNA as novel technology for passive immunotherapy
Schlake, T., Theß, A., Thran, M., & Jordan, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 135
Hartung, H.-P., Mouthon, L., Ahmed, R. A., Jordan, S. C., Laupland, K. B., & Jolles, S. R. A. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04024.x · Cited by 127
Antibody-Based Therapies for Emerging Infectious Diseases
Casadevall, A. (1996) · Emerging infectious diseases · doi:10.3201/eid0203.960306 · Cited by 123
Self-citationStreicher, L. M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.12.025 · Cited by 112
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
Dadachova, E., Nakouzi, A. S., Bryan, R. A., & Casadevall, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1731272100 · Cited by 107
Self-citationVaccines, coming of age after 200 years
Mäkelä, P. H. (2000) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2000.tb00530.x · Cited by 106
Mechanisms of Naturally Acquired Immunity to Streptococcus pneumoniae
Ramos‐Sevillano, E., Ercoli, G., & Brown, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00358 · Cited by 109
Casadevall, A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4225-4228.2003 · Cited by 104
Self-citationA Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals
Casadevall, A., Joyner, M. J., & Pirofski, L. (2020) · JAMA · doi:10.1001/jama.2020.10218 · Cited by 102
Self-citationTaborda, C. P., & Casadevall, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.2100 · Cited by 99
Self-citationStrategies for the control of pneumococcal diseases
Mulholland, K. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00112-7 · Cited by 101
Forthal, D. N. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch2 · Cited by 102
Human Immunoglobulin as a Treatment for West Nile Virus Infection
Agrawal, A. G., & Petersen, L. R. (2003) · The Journal of Infectious Diseases · doi:10.1086/376871 · Cited by 96
History and Practice: Antibodies in Infectious Diseases
Hey, A. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0026-2014 · Cited by 91
Staphylococcal vaccines and immunotherapy: to dream the impossible dream?
Projan, S., Nesin, M., & Dunman, P. M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.005 · Cited by 88
Passive Antibody Therapies: Progress and Continuing Challenges
Casadevall, A. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4768 · Cited by 87
Self-citationThe role of phage display in therapeutic antibody discovery
Chan, C. E. Z., Lim, A. P. C., MacAry, P. A., & Hanson, B. J. (2014) · International Immunology · doi:10.1093/intimm/dxu082 · Cited by 87
A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis
de Kruif, J., Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Throsby, M., Rupprecht, C. E., & Goudsmit, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145053 · Cited by 88
A Human IgM Monoclonal Antibody Prolongs Survival of Mice with Lethal Cryptococcosis
Fleuridor, R., Zhong, Z., & Pirofski, L. (1998) · The Journal of Infectious Diseases · doi:10.1086/515688 · Cited by 83
Hüebner, J., Quaas, A. M., Krueger, W. A., Goldmann, D. A., & Pier, G. B. (2000) · Infection and Immunity · doi:10.1128/iai.68.8.4631-4636.2000 · Cited by 83
Antibodies: an alternative for antibiotics?
Berghman, L., Abi-Ghanem, D., Waghela, S. D., & Ricke, S. C. (2005) · Poultry Science · doi:10.1093/ps/84.4.660 · Cited by 82
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
Casadevall, A., Pirofski, L., & Joyner, M. J. (2021) · mBio · doi:10.1128/mbio.03372-20 · Cited by 77
Self-citationAntibody production: Polyclonal-derived biotherapeutics
Newcombe, C., & Newcombe, A. R. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.004 · Cited by 78
Anti-bacterial monoclonal antibodies: Back to the future?
Oleksiewicz, M. B., Nagy, G., & Nagy, E. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.06.001 · Cited by 75
Manoff, S. B., Liss, C. L., Caulfield, M. J., Marchese, R. D., Silber, J. L., Boslego, J. W., Romero‐Steiner, S., Rajam, G., Glass, N. E., Whitney, C. G., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651131 · Cited by 71
Crisis in Infectious Diseases: Time for a New Paradigm?
Casadevall, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.4.790 · Cited by 70
Self-citationPucelik, B., & Dąbrowski, J. M. (2022) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2021.12.003 · Cited by 71
Fleuridor, R., Lyles, R. H., & Pirofski, L. (1999) · The Journal of Infectious Diseases · doi:10.1086/315102 · Cited by 68
Senefeld, J. W., Johnson, P. W., Kunze, K. L., Bloch, E. M., van Helmond, N., Golafshar, M. A., Klassen, S. A., Klompas, A. M., Sexton, M. A., Soto, J. C. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003872 · Cited by 66
Self-citationYano, A., Maeda, F., & Takekoshi, M. (2004) · Journal of Medical Virology · doi:10.1002/jmv.20077 · Cited by 63
IgY antibodies: The promising potential to overcome antibiotic resistance
El-Kafrawy, S. A., Abbas, A. T., Oelkrug, C., Tahoon, M. A. H., Ezzat, S., Zumla, A. I., & Azhar, E. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1065353 · Cited by 65
Grabenstein, J. D., & Manoff, S. B. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.052 · Cited by 61
Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection
Dadachova, E., Burns, T., Bryan, R. A., Apostolidis, C., Brechbiel, M. W., Nosanchuk, J. D., Casadevall, A., & Pirofski, L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1624-1629.2004 · Cited by 60
Self-citationChicken egg yolk antibody (IgY) as diagnostics and therapeutics in parasitic infections – A review
Diraviyam, T., Ambi, S. V., Vieira-Pires, R. S., Zhang, X., Sekaran, S., & Krishnan, U. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.06.118 · Cited by 60
Prospects for the development of fungal vaccines
Deepe, G. S. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.585 · Cited by 59
Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies
Boniche-Alfaro, C., Rossi, S. A., Kischkel, B., Barbalho, F. V., Moura, Á. N. D., Nosanchuk, J. D., Travassos, L. R., & Taborda, C. P. (2020) · Journal of Fungi · doi:10.3390/jof6010031 · Cited by 59
Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody
Lee, S. C., Kress, Y., Dickson, D. W., & Casadevall, A. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00097-l · Cited by 55
Self-citationMonoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy
Mukherjee, J., Feldmesser, M., Scharff, M. D., & Casadevall, A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1398 · Cited by 54
Self-citationPotent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
Prabakaran, P., Zhu, Z., Xiao, X., Biragyn, A., Dimitrov, A. S., Broder, C. C., & Dimitrov, D. S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902763755 · Cited by 51
Glatman‐Freedman, A. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00172-x · Cited by 52
Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies
Zhong, Z., & Pirofski, L. (1996) · Infection and Immunity · doi:10.1128/iai.64.9.3446-3450.1996 · Cited by 51
Immunomodulators as an antimicrobial tool
Pirofski, L., & Casadevall, A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.004 · Cited by 50
Self-citationMonoclonal Antibodies and Toxins—A Perspective on Function and Isotype
Chow, S.-K., & Casadevall, A. (2012) · Toxins · doi:10.3390/toxins4060430 · Cited by 49
Self-citationThe Emerging Role of Convalescent Plasma in the Treatment of COVID‐19
Ψαλτοπούλου, Θ., Sergentanis, T. Ν., Pappa, V., Politou, M., Terpos, E., Tsiodras, S., Pavlakis, G. N., & Dimopoulos, M. A. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000409 · Cited by 48
Tian, H., Weber, S., Thorkildson, P., Kozel, T. R., & Pirofski, L. (2009) · Infection and Immunity · doi:10.1128/iai.01075-08 · Cited by 48
The Third Age of Antimicrobial Therapy
Casadevall, A. (2006) · Clinical Infectious Diseases · doi:10.1086/503431 · Cited by 48
Self-citationConvalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
Ripoll, J. G., van Helmond, N., Senefeld, J. W., Wiggins, C. C., Klassen, S. A., Baker, S. E., Larson, K. F., Murphy, B. M., Andersen, K. J., Ford, S. K., et al. (2021) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2021.02.001 · Cited by 46
Self-citationChang, Q., Zhong, Z., Lees, A., Pekna, M., & Pirofski, L. (2002) · Infection and Immunity · doi:10.1128/iai.70.9.4977-4986.2002 · Cited by 46
Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections
Seixas, A. M. M., Sousa, S. A., & Leitão, J. H. (2022) · Vaccines · doi:10.3390/vaccines10111789 · Cited by 44
Cryptococcus neoformans: Paradigm for the Role of Antibody Immunity Against Fungi?
Pirofski, L., & Casadevall, A. (1996) · Zentralblatt für Bakteriologie · doi:10.1016/s0934-8840(96)80001-6 · Cited by 43
Self-citationAntifungal Activity of a Human Antiglucuronoxylomannan Antibody
Zhong, Z., & Pirofski, L. (1998) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.5.1.58-64.1998 · Cited by 43
Convalescent plasma therapy in patients with COVID ‐19
Yiğenoğlu, T. N., Hacıbekiroğlu, T., Berber, İ., Dal, M. S., Baştürk, A., Namdaroğlu, S., Korkmaz, S., Ulaş, T., Dal, T., Erkurt, M. A., et al. (2020) · Journal of Clinical Apheresis · doi:10.1002/jca.21806 · Cited by 43
Deciphering SARS-CoV-2 Virologic and Immunologic Features
Lebeau, G., Vagner, D., Frumence, É., Ah-Pine, F., Guillot, X., Nobécourt, E., Raffray, L., & Gasque, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165932 · Cited by 54
Bartlett, B. L., Pellicane, A. J., & Tyring, S. K. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01223.x · Cited by 40
The use of antibodies in the treatment of infectious diseases.
Chan, C. E. Z., Chan, A. H., Hanson, B. J., & Ooi, E. E. (2009) · PubMed · Cited by 40
Zhong, Z., Burns, T., Chang, Q., Carroll, M. C., & Pirofski, L. (1999) · Infection and Immunity · doi:10.1128/iai.67.8.4119-4127.1999 · Cited by 40
Slifka, M. K., & Amanna, I. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00008-0 · Cited by 43
Saylor, C., Dadachova, E., & Casadevall, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902752 · Cited by 36
Self-citationProduction of recombinant antibodies using bacteriophages
Shukra, A. M., Sridevi, N., Chandran, D., & Maithal, K. (2014) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.4.2014.2.1 · Cited by 38
Domenech, M., Sempere, J., de Miguel, S., & Yuste, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02700 · Cited by 37
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
Santis, G. C. D., de Oliveira, L. C. O., Garibaldi, P. M. M., Almado, C. E. L., Croda, J., Arcanjo, G. G. D. A., Oliveira, É. A. F., Tonacio, A. C., Langhi, D. M., Bordin, J. O., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2803.212299 · Cited by 35
Liedke, S. C., Zamith‐Miranda, D., Gomes, K. X., Gonçalves, J. L. S., Frasés, S., Nosanchuk, J. D., Rodrigues, M. L., Nimrichter, L., Peralta, J. M., & Guimaraes, A. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-12540-y · Cited by 35
Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans
Mukherjee, J., Cleare, W., & Casadevall, A. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00097-t · Cited by 35
Self-citationStructural investigation of humanS. aureus-targeting antibodies that bind wall teichoic acid
Fong, R., Kajihara, K. K., Chen, M., Hötzel, I., Mariathasan, S., Hazenbos, W. L. W., & Lupardus, P. J. (2018) · mAbs · doi:10.1080/19420862.2018.1501252 · Cited by 34
Casadevall, A., Joyner, M. J., Pirofski, L., Senefeld, J. W., Shoham, S., Sullivan, D. J., Paneth, N., & Focosi, D. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2208349 · Cited by 32
Self-citation
Metadata
- Authors
- Casadevall, A., & Scharff, M. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1994-08
- Volume
- 38
- Issue
- 8
- Pages
- 1695-1702
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC284624
- OpenAlex
- W2031152984
- Cited by
- 251
- References
- 84
- Citations by year
- 2025: 8 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 20 · 2020: 29 · 2019: 5 · 2018: 7 · 2017: 10 · 2016: 4 · 2015: 6 · 2014: 12 · 2013: 6 · 2012: 8
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-39839)
- National Institute of Allergy and Infectious Diseases (AI13342, AI33774, R01AI033774)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- serum therapy, animal models of infection, passive antibody therapy, passive immunization
- MeSH terms
- Animals, Disease Models, Animal, Humans, Immunization, Passive, Meningitis, Meningococcal, Pneumococcal Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
